Search results

Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.

Result type

Technology appraisal guidance

Published

21 December 2016

Evidence-based recommendations on venetoclax (Venclyxto) with azacitidine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.

Result type

Technology appraisal guidance

Published

2 February 2022

Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.

Result type

Technology appraisal guidance

Published

20 December 2017

Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after hip or knee replacement in adults.

Result type

Technology appraisal guidance

Published

25 January 2012

Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.

Result type

Technology appraisal guidance

Published

12 February 2025

Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

Result type

Technology appraisal guidance

Last updated

2 July 2021

Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.

Result type

Technology appraisal guidance

Published

25 March 2015

Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults when systemically administered immunotherapies are not suitable.

Result type

Technology appraisal guidance

Published

28 September 2016

Recommendation ID NG101/6 Question Neoadjuvant treatment:- What are the indications for postmastectomy radiotherapy after neoadjuvant...

Result type

Research recommendation

Published

11 December 2018

Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating spinal muscular atrophy in babies.

Result type

Highly specialised technologies guidance

Last updated

19 April 2023

Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

Result type

Technology appraisal guidance

Published

28 September 2016

This quality standard covers assessment, early management and rehabilitation following head injury in adults, young people and children. It describes high-quality care in priority areas for improvement.

Result type

Quality standard

Last updated

15 October 2025

Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.

Result type

Technology appraisal guidance

Published

24 April 2013

Evidence-based recommendations on evinacumab (Evkeeza) for treating homozygous familial hypercholesterolaemia in people 12 years and over.

Result type

Technology appraisal guidance

Published

11 September 2024

Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults.

Result type

Technology appraisal guidance

Published

26 July 2017

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults.

Result type

Technology appraisal guidance

Published

14 June 2023

Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention for treating acute coronary syndromes in adults.

Result type

Technology appraisal guidance

Published

23 July 2014

Evidence-based recommendations on tofacitinib (Xeljanz) for treating active ankylosing spondylitis.

Result type

Technology appraisal guidance

Published

18 October 2023

Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.

Result type

Technology appraisal guidance

Published

28 February 2023

Evidence-based recommendations on givosiran (Givlaari) for treating acute hepatic porphyria in adults and young people aged 12 and over.

Result type

Highly specialised technologies guidance

Published

24 November 2021

Evidence-based recommendation on linzagolix (Yselty) for treating symptoms of endometriosis in adults of reproductive age.

Result type

Technology appraisal guidance

Published

4 June 2025

Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.

Result type

Technology appraisal guidance

Published

18 December 2019

Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.

Result type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.

Result type

Technology appraisal guidance

Published

24 August 2016

Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16.

Result type

Highly specialised technologies guidance

Published

22 February 2017

Recommendation ID TA287/2 Question Research into the long-term treatment effects of rivaroxaban is needed. Any explanatory notes(if...

Result type

Research recommendation

Published

9 June 2015

Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

Result type

Technology appraisal guidance

Published

26 June 2013

This guideline covers assessment of people aged 16 and over with symptoms and signs of acute respiratory infection (bacterial or viral) at first remote or in-person contact with NHS services. It also covers the initial management of any infections. It aims to support healthcare practitioners in making sure that people’s treatment follows the best care pathway. It forms part of a suite of work on virtual wards being undertaken by NICE.

Result type

NICE guideline

Last updated

2 September 2025

Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults.

Result type

Technology appraisal guidance

Last updated

12 September 2017

Awaiting development Reference number: GID-TA11720 Expected publication date: TBC

Result type

Technology appraisal guidance

Status

Awaiting development

Awaiting development Reference number: GID-TA11048 Expected publication date: TBC

Result type

Technology appraisal guidance

Status

Awaiting development

Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.

Result type

Technology appraisal guidance

Published

12 August 2020

Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.

Result type

Technology appraisal guidance

Published

3 February 2021

Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.

Result type

Technology appraisal guidance

Published

5 January 2022

Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.

Result type

Technology appraisal guidance

Published

25 January 2017

Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.

Result type

Technology appraisal guidance

Published

18 December 2019

Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.

Result type

Technology appraisal guidance

Published

1 February 2023

Evidence-based recommendations on ibrutinib (Imbruvica) for treating relapsed or refractory mantle cell lymphoma in adults.

Result type

Technology appraisal guidance

Published

31 January 2018

Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

29 June 2022

Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

Result type

Technology appraisal guidance

Published

22 June 2016

Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

Result type

Technology appraisal guidance

Published

22 June 2016

This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

Result type

NICE guideline

Last updated

2 October 2023

Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults.

Result type

Technology appraisal guidance

Published

19 September 2018

Question What is the effectiveness of hormone-modifying agents in the treatment of acne vulgaris? Any explanatory notes(if applicable)...

Result type

Research recommendation

Published

3 May 2024

Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.

Result type

Technology appraisal guidance

Published

9 August 2017

Evidence-based recommendations on ataluren (Translarna) for Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people 2 years and over who can walk.

Result type

Highly specialised technologies guidance

Published

22 February 2023

Non-metformin-based drug treatment combinations to control blood glucose levels: In adults with type 2 diabetes, what...

Result type

Research recommendation

Published

16 December 2021

Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.

Result type

Technology appraisal guidance

Published

8 May 2024

Recommendation ID CG185/2 Question Maintenance treatment:- In the maintenance treatment of bipolar disorder, what is the...

Result type

Research recommendation

Published

9 June 2015

This quality standard covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It describes high-quality care in priority areas for improvement.

Result type

Quality standard

Published

2 March 2023